

Frdric Charlotte

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8523501/frederic-charlotte-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

3,097
citations

24
h-index

55
g-index

57
ext. papers

3,863
ext. citations

3.9
avg, IF

4.53
L-index

#	Paper	IF	Citations
53	Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
52	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021 , 137, 485-492	2.2	8
51	Temporal arteritis in IgG4 related disease. <i>Joint Bone Spine</i> , 2021 , 88, 105087	2.9	3
50	Quantitative and Qualitative Approach for Shear Wave Elastography in Superficial Lymph Nodes. <i>Ultrasound in Medicine and Biology</i> , 2021 , 47, 2117-2127	3.5	1
49	Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. <i>Blood Advances</i> , 2020 , 4, 2501-2515	7.8	6
48	Erdheim-Chester disease: a rapidly evolving disease model. <i>Leukemia</i> , 2020 , 34, 2840-2857	10.7	10
47	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 828-838	13.4	22
46	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 998-1007	2.2	5
45	Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia. <i>Advanced Therapeutics</i> , 2020 , 3, 2000131	4.9	6
44	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by. <i>Haematologica</i> , 2020 , 105, e5-e8	6.6	20
43	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. <i>Haematologica</i> , 2019 , 104, e502-e505	6.6	9
42	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 393-402	2.2	8
41	Reply. <i>Arthritis and Rheumatology</i> , 2019 , 71, 171-172	9.5	1
40	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 308-320	6.1	8
39	Highly sensitive methods are required to detect mutations in histiocytoses. <i>Haematologica</i> , 2019 , 104, e97-e99	6.6	13
38	Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1481-1488	9.5	34
37	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , 2018 , 93, E114-E117	7.1	53

36	Efficacy of infliximab in the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1387-1390	2.4	18
35	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. <i>Blood</i> , 2018 , 131, 2877-2890	2.2	185
34	Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018 , 9, 10	8.4	28
33	Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm. <i>Diagnostic Cytopathology</i> , 2018 , 46, 639-641	1.4	3
32	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. <i>Blood</i> , 2018 , 132, 4380-4380	2.2	
31	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1117-1127	6.1	14
30	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology, The</i> , 2017 , 18, e113-e125	21.7	124
29	The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2443-2453	5.6	37
28	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017 , 130, 176-180	2.2	60
27	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017 , 130, 1007-1013	2.2	69
26	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017 , 130, 1377-1380	2.2	95
25	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000075	3.9	62
24	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 513-20	4.5	52
23	Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from an Ex Vivo Animal Model on Pig Eyes. <i>Journal of Endourology</i> , 2016 , 30, 332-7	2.7	18
22	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e19074-e19074	2.2	
21	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. <i>Blood</i> , 2016 , 127, 1509-12	2.2	44
20	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016 , 127, 2672-81	2.2	675
19	Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. <i>Blood</i> , 2016 , 128, 1651-9	2.2	73

18	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1033-42	5.1	30
17	SASH1, a new potential link between smoking and atherosclerosis. <i>Atherosclerosis</i> , 2015 , 242, 571-9	3.1	17
16	Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. <i>Journal of Hepatology</i> , 2015 , 62, 816-21	13.4	21
15	Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. <i>Journal of Clinical Oncology</i> , 2015 , 33, 411-8	2.2	186
14	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. <i>Blood</i> , 2015 , 126, 1464-1464	2.2	1
13	Langerhans cell histiocytosis in children: Correlation of BRAF status with clinical characteristic.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10003-10003	2.2	
12	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014 , 124, 3016-9	2.2	157
11	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014 , 124, 1119-26	2.2	163
10	Perirenal fibrosis: make your diagnosis. <i>CKJ: Clinical Kidney Journal</i> , 2013 , 6, 543-4	4.5	1
9	Treatment of Erdheim-Chester disease with long-term high-dose interferon- γ <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 41, 907-13	5.3	63
8	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012 , 120, 2700-3	2.2	469
7	Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe. <i>Blood</i> , 2012 , 120, 1607-1607	2.2	2
6	Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. <i>Blood</i> , 2011 , 117, 2783-90	2.2	113
5	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. <i>Blood</i> , 2010 , 116, 4716-4716	2.2	
4	Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2009 , 31, 782-6	1.2	34
3	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 448, 506-16	5.1	33
2	Blood Flow Cytometry Allows Us To Dispense with Bone Marrow Biopsy in the Evaluation of Treatment Response in CLL.. <i>Blood</i> , 2004 , 104, 4769-4769	2.2	
1	Highly selective inhibitor of inducible nitric oxide synthase enhances S-antigen-induced uveitis. <i>Current Eye Research</i> , 2003 , 26, 1-7	2.9	6

